When was ASLAN Pharmaceuticals founded?

ASLAN Pharmaceuticals was founded in 2010 and raised its 1st funding round within a year of its incorporation.

Where is ASLAN Pharmaceuticals located?

ASLAN Pharmaceuticals is headquartered in Singapore, Singapore. It is registered at 83 CLEMENCEAU AVENUE #12-03 UE SQUARE SINGAPORE 239920.

Who is the current CEO of ASLAN Pharmaceuticals?

Carl Firth of ASLAN Pharmaceuticals.

How many employees does ASLAN Pharmaceuticals have?

As of Mar 01, 2026, the latest employee count at ASLAN Pharmaceuticals is 10 - 49.

Is ASLAN Pharmaceuticals a funded company?

ASLAN Pharmaceuticals is a funded company, having raised a total of $100M across 9 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jul 27, 2010.

When was the latest funding round of ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals' latest funding was a $***** Post IPO round on Mar 02, 2023, with participation from 2 investors. Its primary sector is Dermatology. In Singapore, the Dermatology sector has seen $20.5M in funding in 2026 to date.

Where does ASLAN Pharmaceuticals rank among its competitors?

ASLAN Pharmaceuticals ranks 3rd amongst 20 active competitors, of which 6 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Bionyra, which secured $165M in Jun, 2026.

Who are the top competitors of ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals' top competitors include RAPT, Biosion and Forte Biosciences. Among them, Bionyra secured the most recent funding round in June, 2026.

ASLAN Pharmaceuticals - 2026 Company Profile, Team, Funding, Competitors & Financials

ASLAN Pharmaceuticals is a public company based in Singapore (Singapore), founded in 2010 by Carl Firth. It operates as a Targeted small molecules for cancer treatment. ASLAN Pharmaceuticals has raised $100M in funding from investors like MVP Capital Partners, Milestone Capital and Cenova. The company has 20 active competitors, including 6 funded and 6 that have exited. Its top competitors include companies like RAPT, Biosion and Forte Biosciences.

Company Details

ASLAN Pharmaceuticals is an oncology-focused company developing a portfolio of targeted drugs, focusing on gastric, bile duct and breast cancers. The Company’s proprietary pipeline of 4 development-stage candidates addresses multiple indications including gastric and breast cancers and inflammatory diseases. ASLAN’s most advanced compounds are ASLAN001 which is pan-HER inhibitor with phase 2 data in gastric cancer, being developed in cholangiocarcinoma, breast cancer and gastric cancer, and ASLAN002, which targets RON, an immune checkpoint inhibitor, and cMET receptor tyrosine kinases, being developed in gastric and breast cancer.

Website: aslanpharma.com
Social
Registered Address: 83 CLEMENCEAU AVENUE #12-03 UE SQUARE SINGAPORE 239920

Key Metrics

Founded Year

2010

Location

Singapore, Singapore

Stage

Public

Total Funding

$100M in 9 rounds

Latest Funding Round

Post IPO, Mar 02, 2023, $*****

Investors

MVP Capital Partners & 16 more

Ranked

3^rd among 20 active competitors

Employee Count

10 - 49 as on Mar 01, 2026

Similar Companies

RAPT & 20 more

Exit Details

Public

View ASLAN Pharmaceuticals' full profile

ASLAN Pharmaceuticals is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Aslan Pharmaceuticals Pte Ltd UEN: 201007695N , Singapore, Active	Dec 31, 2009	-	-

ASLAN Pharmaceuticals got listed on Dec 06, 2019.

Click here to take a look at ASLAN Pharmaceuticals's IPO in detail

ASLAN Pharmaceuticals has raised a total funding of $100M over 9 rounds. Its first funding round was on Jul 27, 2010. Its latest funding round was a Post IPO round on Mar 02, 2023 for $*****. 2 investors participated in its latest round. ASLAN Pharmaceuticals has 17 institutional investors.

Here is the list of recent funding rounds of ASLAN Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 02, 2023	7962052	Post IPO	8930281	8542145	6806900	2227795
Feb 25, 2021	6415710	Post IPO	3946725	4883680	5477807	1471788
Oct 18, 2019	2618685	Conventional Debt	4943145	3112833	1094762	1229795

Access funding benchmarks and valuations. Sign up today!

View details of ASLAN Pharmaceuticals's funding rounds and investors

The founders of ASLAN Pharmaceuticals is Carl Firth.

Here are the details of ASLAN Pharmaceuticals' key team members:

Carl Firth: Founder & CEO of ASLAN Pharmaceuticals.

View details of ASLAN Pharmaceuticals's Founder profiles and Board Members

ASLAN Pharmaceuticals' employee count trend

ASLAN Pharmaceuticals has 10 - 49 employees as of Mar 26. Here is ASLAN Pharmaceuticals's employee count trend over the years:

Employee count trend for ASLAN Pharmaceuticals

Uncover ASLAN Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ASLAN Pharmaceuticals include RAPT, Biosion and Forte Biosciences. Here is the list of Top 10 competitors of ASLAN Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	RAPT 2015, San Francisco (United States), Acquired	Provider of immunology-based drug for oncology and inflammatory diseases	$199M	The Column Group, Celgene & 19 others	59/100
2nd	Biosion 2017, Nanjing (China), Series B	Developer of antibody-based therapeutics to treat various diseases	$76.4M	3E BioVentures, Zheshang Innovation Investment Group ... & 7 others	56/100
3rd	ASLAN Pharmaceuticals 2010, Singapore (Singapore), Public	Targeted small molecules for cancer treatment	$100M	BVF Partners, Sagamore Investment Management ... & 15 others	54/100
4th	Forte Biosciences 2017, Torrance (United States), Acquired	Developer of therapeutic solutions for treating inflammatory skin diseases	-	The Red Hook Fund, BVF Partners & 6 others	52/100
5th	TIRmed Pharma 2018, Bromma (Sweden), Series A	Developer of therapeutic solutions to treat atopic dermatitis	$4.73M	EIC Fund, Europa & 3 others	51/100
6th	UNION Therapeutics 2013, Hellerup (Denmark), Series B	Developer of small molecule antibiotic drugs for treating bacterial infections	$57.1M	European Investment Bank, Eaf Procedius & 7 others	50/100
7th	Concerto Biosciences 2019, Cambridge (United States), Series A	Developer of microbe-based products for agriculture and human health	$24.5M	Safar Partners, Humboldt Fund & 9 others	46/100
8th	PinCell 2008, Milano (Italy), Acquired	Developer of anti-inflammatory therapy for the treatment skin diseases	$1.78M	Sofinnova Partners	44/100
9th	Minghui Pharmaceutical 2018, Hangzhou (China), Unfunded	Developer of therapeutics for cancer and auto-immune diseases	-	-	41/100
10th	Bionyra 2025, Paris (France), Series A	Developer of biologics targeting immune pathways for inflammatory disease treatment	$165M	Sofinnova Partners, Jeito & 5 others	38/100